The primary benefit of 5-HT3 receptor antagonists in cancer treatment is their ability to significantly reduce the incidence and severity of CINV. This improvement in quality of life allows patients to adhere more closely to their chemotherapy regimens, potentially improving their overall outcomes. Additionally, these medications are generally well-tolerated, with few serious side effects.
